Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Tempus AI Inc (NASDAQ:TEM) shares closed up 14.5% following the announcement of expanded strategic partnerships with ...

Many of America’s wealthiest business leaders have lost millions — if not billions — of dollars in net worth since the start of the year, as President Donald Trump’s policies hit markets. But some ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

Chuck Davis, Mark Zuckerberg, Jamie Dimon, and Max de Groen were among other top executives who sold their stake in their ...

Cohen’s personal worth now sits at $3.3 billion, most of it tied to Denver-based Palantir options. Eric Lefkofsky, CEO of ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing across all major diseases.

Tempus CEO Eric Lefkofsky outlined the expansion opportunity at a Morgan Stanley event last month. The company is currently focused on oncology, which Lefkofsky said accounts for $1 trillion of ...